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ABSTRACT
In spite of increased awareness and the efforts
taken to optimize Clostridium difficile infection
(CDI) management, with the limited number of
currently available antibiotics for C. difficile the
halt of this increasing epidemic remains out of
reach. There are, however, close to 80
alternative treatment methods with
controversial anti-clostridial efficacy or in
experimental phase today. Indeed, some of
these therapies are expected to become
acknowledged members of the recommended
anti-CDI arsenal within the next few years.
None of these alternative treatment methods
can respond in itself to all the major challenges
of CDI management, which are primary
prophylaxis in the susceptible population,
clinical cure of severe cases, prevention of
recurrences, and forestallment of
asymptomatic C. difficile carriage and
in-hospital spread. Yet, the greater the variety
of treatment choices on hand, the better
combination strategies can be developed to
reach these goals in the future. The aim of this
article is to provide a comprehensive summary
of these experimental and currently off-label
therapeutic options.
Keywords: Clinical development pipeline;
Clostridium difficile infection (CDI);
Controversial therapies; Experimental therapies
INTRODUCTION
Clostridium difficile infection (CDI) has been
increasingly recognized in recent years as an
entity of primary importance that requires
prompt diagnosis and efficient treatment to
prevent a severe and complicated disease
course, in-hospital spread and recurrences.
However, due to the spore-forming ability of
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C. difficile, the impaired host intestinal
microbiota and the altered immunity of CDI
patients, current treatment strategies often have
suboptimal results with regard to clinical cure
and relapse prevention alike. In fact, present
therapeutic options leave ample room for
improvement in terms of clinical outcome, as
the average cure rates achieved by the three
main antibiotics currently recommended for
CDI treatment (metronidazole, vancomycin
and fidaxomicin [1, 2]) do not exceed 80–90%
[3]. Although fidaxomicin boasts significantly
lower relapse rates than the other two
alternatives, sustained cure (that is cure
without recurrence) may be as low as 75%
among patients treated with this best available
option [4, 5].
The urgent need for more efficient tools to
fight CDI makes it unsurprising that today there
are an impressive number of novel antibiotics
and other therapies at different stages of
development, some of them already being
tested in phase III randomized controlled trials
(RCTs). At the same time, some long-known
drugs that are currently not recommended for
CDI have been revisited lately to check whether
there is potential room for them in the arsenal
of anti-CDI therapeutics. The aim of this review
is to summarize novel, neglected and
controversial CDI treatment options, some of
which may become part of everyday practice in
the near future.
There are various criteria according to which
one may classify these therapies (mode of
administration, predominantly prophylactic
vs. therapeutic agents, natural vs. synthetic
products, etc.). In this article we resume them
according to the major therapeutic effect that is
sought by their application (Fig. 1).
Accordingly, the majority of these products
can fit in one of the following categories: (1)
antibiotics and non-antibiotic agents with
bacteriostatic/bactericidal effect against C.
difficile; (2) toxin-neutralizing agents; (3)
therapies that boost host immune defense
against CDI; (4) treatments that modulate the
intestinal environment to make it less favorable
for C. difficile colonization; (5)
anti-inflammatory substances that prevent or
reduce enterocyte damage caused by C. difficile
toxins. Table 1 summarizes all therapies
discussed in the following, along with their
current phase of development.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of





Similarly to the three main currently
recommended anti-clostridial drugs, the
majority of off-label and experimental
therapeutic options seek to have a direct effect
on the causative microorganism. These
antibiotics and non-antibiotic agents target
certain molecular components of C. difficile
with the aim of eliminating the bacteria in an
already established infection. They are
presented in the following, grouped according
to their main mechanism of action.
Inhibitors of Transcription and DNA
Synthesis
Rifamycins
Rifaximin is a semisynthetic, nonabsorbable
derivative of rifamycin that inhibits bacterial
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RNA synthesis, primarily used in the treatment
of traveler’s diarrhea and hepatic
encephalopathy. It is considered to have very
little and rather beneficial effect on the normal
intestinal microbiota [6, 7], though its complete
innocuousness in patients receiving long-term
rifaximin treatment is questionable [8]. It was
equally efficient as vancomycin in a hamster
model of CDI, and—depending on the C.
difficile strain used—similar or lower recurrence
rates were observed after rifaximin withdrawal
as compared to the vancomycin group [9].
There have been various retrospective and
prospective clinical case series demonstrating
its efficacy in first CDI episodes, as well as in
recurrent and refractory CDI [10–13], but
rifaximin failed to unmistakably demonstrate
non-inferiority to vancomycin in a RCT [14]. Its
somewhat higher resistance rates as compared
to vancomycin and metronidazole—especially
Fig. 1 Major events in Clostridium difﬁcile infection
pathogenesis as therapeutic targets of investigational anti-CDI
treatments. A Disruption of healthy gut microbiota and C.
difﬁcile colonization—therapy aiming to protect or to restore
the intestinal microbiota; B C. difﬁcile germination and
outgrowth—antibiotics and non-antibiotic agents targeting
C. difﬁcile; C toxin secretion—toxin-neutralizing agents;
D toxin-mediated enterocyte damage and activation of the
innate immune system—therapy aiming to alleviate intestinal
mucosa inﬂammation; E adaptive immune system
activation—active immunotherapy. The ﬁgure does not
pretend to depict the entire process in its completeness but
rather focuses on themain steps that are interferedwith by the
different treatment modalities detailed in the article.
Important components of C. difﬁcile pathogenesis and host
defense (endosomes, cytoskeleton, dendritic cells,mucus layer,
bile acids, etc.) are deliberately missing from the image
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in binary toxin negative strains—and the
possibility of resistance emergence during CDI
therapy are additional issues of concern [15–19].
Today it may only be recommended as a
‘‘chaser’’ therapy after vancomycin treatment
to reduce CDI recurrence risk [20], based on the
results of case series [19, 21] and a small RCT
[22]. A larger phase IV RCT to verify these data is
currently recruiting participants [23].
Rifalazil is another rifamycin derivative,
which conferred significantly lower
mortality—both administered prophylactically
and therapeutically—in a hamster CDI model,
as compared to vancomycin [24]. However, no
studies on its efficacy in human CDI have been
published until now.
Other Agents
Kibdelomycin is a novel inhibitor of type II and
IV topoisomerases developed by Merck, which
possesses high in vitro activity against various
C. difficile strains [25]. Encouraging results were
obtained with it in a hamster model of CDI in
terms of survival (80–100%), bacterial
elimination (2- to 5-log reduction of C. difficile
counts) and a practically absent enteral
absorption [25]. Upcoming phase I human
trials have not yet been announced.
MGB Biopharma is developing a compound,
MGB-BP-3, that interferes with the transcription
of C. difficile DNA by binding directly to certain
sequences on its minor groove [26]. It reduced
both vegetative cell and spore count of intestinal
C. difficile to a greater extent than vancomycin in
an animal model [26], and it was well tolerated
without raising major safety issues in a recent
phase I human trial [27]. The initiation of a phase
II trial with this compound is one of the major
immediate objectives of the company [28].
OPS-2071 is a quinolone-based
investigational compound under development
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completed phase I trials [29], a phase II clinical
trial is currently recruiting subjects to evaluate
its efficacy and safety in CDI patients [30].
Inhibitors of Protein Synthesis
Tetracyclines
Tigecycline is the first member of the novel
glycylcycline antibiotic family with a broad
antimicrobial spectrum that inhibits protein
synthesis by blocking the entry of
aminoacyl-tRNA into the ribosome by
binding to the 30S subunit [31]. Apart from
possessing activity against a wide range of
gram-positive and gram-negative bacteria,
including multi-resistant strains, tigecycline
inhibits both toxin production and
sporulation of C. difficile in vitro [32, 33].
Although due to its wide spectrum tigecycline
may alter the intestinal microbiota
significantly, thus potentially facilitating
primary and recurrent CDI [34], there are
various reports about its efficacy as an
anti-CDI agent in both animal studies [35]
and the real-life clinical setting [36–40]. Solid
evidence originating from RCTs, however, is
still lacking. Consequently, the place of
tigecycline in the CDI treatment hierarchy is
still dubious, but it may be considered as a
good substitute for other broad-spectrum
antibiotics in appropriate cases when
withdrawal of concomitant systemic
antibiotic treatment at CDI diagnosis is not
possible.
Omadacycline is a new aminomethylcycline
antibiotic that binds to the tetracycline
binding-site of the bacterial 30S ribosome
subunit, and it has considerable potency
against gram-positive bacteria [41]. It also
demonstrated high in vitro activity against C.
difficile and was superior to vancomycin in
terms of survival in a hamster model of CDI
[42]. Its clinical evaluation in human CDI has
not yet been undertaken.
Other Agents
Fusidic acid is an inhibitor of elongation factor
G that can act in a bacteriostatic or bactericidal
manner depending on its concentration and
exhibits good in vitro activity against C. difficile
[43]. It was compared with vancomycin and
metronidazole in an RCT [44] and with
metronidazole in another one [45], showing
comparable efficacy to its comparators in both
studies. In one of these trials, however,
significantly higher CDI recurrence rates were
observed in patients receiving fusidic acid
treatment than in the vancomycin and
metronidazole groups [44]. Another concern
with regards to fusidic acid is the relatively
frequent emergence of resistant C. difficile
strains during treatment, which also limits its
routine use [46].
A semisynthetic thiopeptide antibiotic,
LFF571, interferes with bacterial protein
synthesis by inhibiting the delivery of
aminoacyl-tRNA to the ribosome. Its average
MIC values against C. difficile fall between the
ones observed with fidaxomicin and
vancomycin [47, 48], but it does not seem to
be affected by mutations conferring resistance
to these antibiotics [49]. It was tested against
and proved superior to vancomycin in a
hamster model of CDI in terms of survival and
recurrence [50], and it was non-inferior to
vancomycin in a phase II human study [51].
Novartis, the company behind LFF571, has not
announced forthcoming phase III trials with
this compound for the time being.
CRS3123 (previously REP3123) is an
experimental drug against CDI with a novel
mechanism of action, namely the inhibition of
C. difficile methionyl-tRNA synthetase, which is
an essential enzyme for bacterial protein
Infect Dis Ther (2017) 6:1–35 9
synthesis. It proved to be highly active against
C. difficile without significantly affecting major
representatives of the normal intestinal
microbiota [52, 53]. The superiority of
CRS3123 to vancomycin and metronidazole
was demonstrated in terms of inhibition of
toxin formation and sporulation in vitro and
also in terms of survival in an in vivo model
[54]. According to the developer, Crestone
Pharma, phase I studies with CRS3123 are
currently underway [55].
RBx 11760, a biaryl oxazolidinone, was
synthesized by Ranbaxy Research Laboratories.
It inhibits sporulation and also has a
considerable effect on C. difficile toxin
production [56]. In an in vivo model of CDI
the hamsters treated with RBx 11760 had longer
survival than the ones receiving vancomycin or
metronidazole [56].
RBx 14255 is a new ketolide antibiotic
developed by the same company as RBx
11760. It showed similar in vitro activity
against C. difficile as vancomycin and
metronidazole, but proved superior to both of
them in terms of survival in an animal model
[57].
Since Ranbaxy merged into Sun
Pharmaceutical Industries in 2015, the future
fate of these last two investigational
compounds is unsure.
Antisense antibiotic therapy is a novel
antimicrobial treatment method that aims to
block the expression of key microbial genes by
means of the binding of single-stranded
oligomers to the corresponding
complementary mRNA of the microorganism
[58]. A recent study demonstrated the efficacy
of this novel therapy against C. difficile in vitro
[59]. The authors observed significant
inhibition of bacterial growth with the
addition of phosphorothioate gapmer
antisense oligonucleotides complementary to
C. difficile mRNAs coding essential bacterial
enzymes [59]. This revolutionary treatment
method has been tested in various animal
models of bacterial infections, but clinical
trials have only been undertaken in viral
infections until today [58].
Inhibitors of Metabolic Pathways
Nitazoxanide is a thiazolide antibiotic by
Romark Laboratories, which interferes with the
metabolism of anaerobic microorganisms by
inhibiting the pyruvate:ferredoxin
oxidoreductase [60]. This compound possesses
potent antiparasitic and antiviral properties [61]
and also showed potent activity against C.
difficile in vitro, including strains with reduced
metronidazole susceptibility [62, 63]. Clinical
trials comparing its efficacy with metronidazole
(phase II) [64] and vancomycin (phase III) [65],
however, were not conclusive, and the
company presently pursues indications other
than CDI for this drug [66].
Amixicile, a derivative of nitazoxanide with
enhanced water solubility, synthesized at the
University of Virginia, was comparable in terms
of clinical cure to vancomycin and fidaxomicin
in a mouse CDI model and resulted in lower
recurrence rates than its comparators [67]. It
does not appreciably affect intestinal
microbiota, and though a considerable
proportion of orally administered amixicile is
intestinally absorbed, it seems to have a more
favorable toxicity profile than nitazoxanide
[68]. Human studies have not been undertaken
with amixicile until today.
Inhibitors of Cell-Wall Formation
Glycopeptides
Glycopeptide antibiotics interfere with bacterial
peptidoglycan synthesis and consequently
10 Infect Dis Ther (2017) 6:1–35
inhibit cell wall formation. Apart from
vancomycin there are a number of newer
members of this family that have been tested
in the treatment of CDI with promising results.
Teicoplanin may be a good alternative to
vancomycin treatment, although save for a
recent observational study [69] no clinical
evidence has been published on its use in the
last 20 years. Theoretically teicoplanin may
even be superior to vancomycin in this setting
since it was reported to have lower MIC values
for C. difficile [70, 71] and patients treated with
teicoplanin had notoriously lower recurrence
rates than the ones receiving vancomycin in the
few RCTs conducted [44, 72, 73]. This difference
was not statistically significant in any of these
studies, but it is to be borne in mind that all of
them had a rather small number of participants.
A Cochrane meta-analysis, on the other hand,
showed significantly better bacteriologic cure
and a close-to-significant advantage in clinical
cure in patients treated with teicoplanin as
compared to the ones receiving vancomycin
treatment [74]. Teicoplanin has had a licensed
indication for CDI since 2013, and its oral
formulation is available in many countries
outside the USA [1].
Ramoplanin also has lower MICs against C.
difficile than vancomycin [75] and maintains its
activity even against strains with reduced
vancomycin susceptibility [76]. Its sporicidal
effect is superior to vancomycin as has been
demonstrated both in vitro and in vivo [77, 78].
A phase II study conducted more than 10 years
ago is the only experience with ramoplanin in
human subjects published [79], though
according to the website of its current
developer (Nanotherapeutics) a phase III RCT
has already been completed and a phase IIb trial
to evaluate its efficacy in CDI relapse prevention
is imminent [80].
A novel lipoglycopeptide, oritavancin,
showed 2–4 times lower MIC values against C.
difficile as compared with vancomycin in an
in vitro study [81]. It was tested against
vancomycin in a human gut model with
similar efficacy in the initial reduction of
toxin levels, but oritavancin impeded
recurrence after drug withdrawal to a greater
extent than vancomycin [82, 83]. In a hamster
model it also proved superior to vancomycin in
the prevention of CDI [84]. It seems that the
capacity of oritavancin to avoid CDI recurrence
lays in its adhesion to dormant C. difficile
spores, promptly eliminating cells at an early
stage of germination [85]. Human studies with
oritavancin in the treatment of CDI are,
however, still lacking.
Demethylvancomycin is a glycopeptid
antibiotic clinically used in China since the
1960s [86]. Certain N-substituted
demethylvancomycin derivatives showed
enhanced activity as compared to vancomycin
against C. difficile strains in an in vitro model
[87], though these findings have not been
verified in in vivo models.
Other Agents
A number of post-translationally modified
bacteriocins (lantibiotics) have been subjects
of research in the laboratories of Novacta
Biosystems in recent years, which showed fair
capacity to inhibit cell-wall synthesis.
Actagardine, though it is not very active
against C. difficile in itself, in combination
with ramoplanin showed a potent synergistic
effect against the majority of C. difficile strains
tested in vitro [88], and a mutant variant of it,
V15F, seems to be twice as active as actagardine
[89]. NVB302 proved to be non-inferior to
vancomycin in a human gut model of CDI
[90], and a successful phase I trial has also
Infect Dis Ther (2017) 6:1–35 11
already been completed with this compound
[91].
A synthetic analog of the naturally occurring
nucleoside-based capuramycin, SQ641, targets
translocase-1, an essential enzyme in bacterial
cell-wall synthesis. It was originally intended to
be an anti-tuberculosis agent, but since it had
good in vitro activity against C. difficile it was
tested in a mouse model of CDI and was
superior to vancomycin in terms of 14-day
survival [92]. The company behind this
compound, Sequella, has not announced
forthcoming human studies for the time being.
Agents with Direct Effect on Cell Wall/Cell
Membrane
Surotomycin (MK-4261, previously CB-183,315)
is a membrane-active cyclic lipopeptide, whose
rights are owned by Merck since its acquisition
of the original developing company, Cubist
Pharmaceuticals, in 2015. It has potent
bactericidal activity against both growing and
stationary phase C. difficile [93]. It is also active
against Enterococci [94] and disrupts intestinal
microbiota only moderately [95, 96], although
this may be sufficient to bring forward
the overgrowth of extended-spectrum
beta-lactamase-producing Klebsiella in
surotomycin-treated patients [97]. On the
other hand, the emergence of resistant C.
difficile or Enterococcus strains during treatment
is possible but fairly unlikely [98, 99]. In a phase
II clinical trial CDI recurrence rates were
significantly lower and sustained clinical
response rates were significantly higher in
patients treated with surotomycin as compared
to the vancomycin-treated control group [100].
However, the results of one of the two recently
completed phase III trials [101] were recently
made public, according to which the
non-inferiority of surotomycin to vancomycin
could not be demonstrated [102]. These
disappointing results may be the explanation
for the absence of surotomycin in Merck’s latest
research pipeline chart [103].
Thuricin CD, a sactibiotic produced by
Bacillus thuringiensis, was proved to possess
narrow-spectrum activity against C. difficile
[104], having very little effect on the rest of the
normal intestinal microbiota [105]. According
to a recent study, the combination of Thuricin
CD with other anticlostridial antibiotics may
have a synergistic effect on biofilms formed by
certain C. difficile strains [106].
Clostridium difficile produces so-called phage
tail-like particles (PTLPs) that successfully
eradicated C. difficile in an in vitro model
[107]. In another study, administration of a
genetically modified PTLP (Avidocin CD), called
Av-CD291.2, successfully prevented C. difficile
colonization in mice without interfering with
the normal colonic flora [108]. The company
behind Av-CD291.2, AvidBiotics, is planning to
start human studies with this compound in the
near future [109].
PLyCD1-174 is the recombinantly expressed
catalytic domain of a prophage endolysin
identified in a C. difficile strain (CD630). It
exerted potent lytic activity against C. difficile
without significantly affecting other
components of the intestinal microbiota in an
ex vivo mouse model [110].
Hybrid Antibiotics and Other Agents
with Multiple Mechanisms of Action
Cadazolid is a new fluoroquinolone-
oxazolidinone antibiotic by Actelion, which
exerts its antibacterial effect principally by the
inhibition of protein synthesis and to a lesser
degree also interferes with bacterial DNA
synthesis [111]. Cadazolid not only has lower
MICs against C. difficile than vancomycin and
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even fidaxomicin [112, 113], but it is also highly
active against vancomycin resistant Enterococci,
a major threat in vancomycin-treated patients,
minimizing the risk of patient colonization by
this much-dreaded bacteria [114]. This,
combined with its potent activity against
toxin formation and sporulation, makes it a
promising new recruit among anticlostridial
drugs. It performed well in a phase II trial as
compared to vancomycin in first episodes or
first recurrences of CDI [115], and it is currently
being tested in two phase III clinical trials [116].
MCB3681, a novel
fluoroquinolone-oxazolidinone antibiotic by
Morphochem, also proved to possess excellent
in vitro efficacy against C. difficile [117]. In a
phase I study its water-soluble prodrug,
MCB3837, was administered intravenously to
healthy individuals and showed a marked
reduction of gram-positive organisms without
considerably affecting the gram-negative
portion of intestinal microbiota [118]. Based
on these data the Food and Drug
Administration recently granted Fast Track
designation to the compound, and the start of
a phase II clinical trial with MCB3837 seems
imminent [119].
MBX-500 (a.k.a compound 251D) is a novel
hybrid antibiotic that binds to three different
bacterial targets: its anilinuracil component acts
as a DNA polymerase inhibitor, and its
fluoroquinolone component blocks DNA
topoisomerase and gyrase enzymes [120]. Its
multiple-site action seems to make the rise of
resistant strains during treatment less probable
[120]. The in vivo efficacy of MBX-500 against
C. difficile was demonstrated in at least three
animal CDI models (hamsters [121], mice [121]
and piglets [122]), but human studies have not
yet been announced by its developer,
Microbiotix.
Ramizol is the first member of a new
antibiotic family that selectively targets the
mechanosensitive ion channel of large
conductance (MscL) in bacteria [123] and
possesses potent antioxidant properties as well
[124]. In a hamster model of CDI orally
administered Ramizol conferred lower 28-day
survival than vancomycin (57% vs. 86%), and
its spore-clearing capacity was also inferior to
that of vancomycin (29–57% vs. 100%) [125].
The company behind it (Boulos and Cooper
Pharmaceuticals), however, is currently working
on a formulation of enhanced efficiency of this
drug [125] and expects to initiate phase I
clinical trials in 2017 [126].
Human a-defensin 5 (HD5) is an enteric
representative of membrane-active
antimicrobial proteins and peptides (AMPs)
produced in the small intestine by Paneth
cells, forming an important, though not yet
truly understood role in host-microbiota
interactions [127]. Its role in C. difficile
toxin-neutralization was suggested by one
study [128], and direct C. difficile cell killing
was observed in another one with physiological
concentrations of HD5 [129]. Whether these
characteristics of HD5 may be exploited in the
fight against C. difficile is unclear.
Certain medium-chain fatty acids, such as
lauric acid derived from virgin coconut oil,
caused a significant inhibition of C. difficile
growth in an in vitro study [130]. It is
postulated that bacterial cell death is caused
by the incorporation of these fatty acids in the
bacterial cell membrane that brings forth a
substantial change in its permeability as well
as by a probable interference with cellular
metabolism [131]. In vivo studies on the
efficacy of virgin coconut oil or its derivatives
in the prevention or treatment of CDI have not
yet been undertaken.
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Agents of Unknown/Unclear Mechanism
of Action
Ridinilazole (previously SMT19969) is a
narrow-spectrum antibiotic with poor oral
bioavailability that exhibits 2–17 times lower
MIC values against C. difficile than vancomycin
[132–134]. Its precise mechanism of action is
not yet fully known, but it had a potent
bactericidal effect on C. difficile, caused
significant reduction of toxin levels and also
demonstrated anti-inflammatory activity
in vitro on human intestinal cells [135]. In a
hamster model, better 28-day survival rates
were observed in animals treated with
ridinilazole than in the ones given
vancomycin or fidaxomicin [136]. A phase II
RCT was completed recently, where ridinilazole
achieved the non-inferiority goal set in terms of
clinical cure and was superior to vancomycin in
terms of sustained clinical response after
30 days of follow-up [137]. Summit
Therapeutics is currently preparing phase III
RCTs with this compound [138].
Berberine is a natural substance already
utilized in ancient Chinese folk medicine. The
addition of berberine to vancomycin
significantly improved mortality, prevented
weight loss and decreased recurrence rates in a
mouse model of CDI [139]. The authors
speculated that berberine may counteract the
deleterious effect of vancomycin on intestinal
microbiota by inhibiting the expansion of
Enterobacteriaceae. A recent in vitro study,
however, showed a high berberine uptake of
germinating C. difficile spores where it may
reach elevated concentrations, inhibiting spore
outgrowth on its own [140].
The bacteriostatic effect of bovine lactoferrin
on Clostridium species has been known for more
than 20 years [141]. As a biomarker for
intestinal inflammation, its fecal
concentrations seem to correlate with CDI
severity [142]. Although it is postulated that
lactoferrin exerts its bacteriostatic activity by
acting as an iron-sequestering agent, in a recent
mouse model of CDI the administration of
iron-saturated—but not iron-depleted—bovine
lactoferrin successfully inhibited C. difficile
toxin production and delayed C. difficile
outgrowth, without significantly affecting the
rest of the intestinal microbiota [143]. A phase II
RCT on its efficacy in the prevention of
antibiotic-associated diarrhea in children is
currently underway [144].
A completely new approach is being
investigated under the aegis of Photobiotics
Ltd., which aims to eradicate C. difficile by
means of radical oxygen species produced by
light-activated photosensitizers. The method,
called Photodynamic Antimicrobial
Chemotherapy (PACT), involves the activation
of a light-sensitive dye (photosensitiser) by
visible light that utilizes the received energy to
generate radical species or singlet oxygen that,
in turn, leads to cell death [145]. In an in vitro
model, 99.9% of C. difficile colonies was
eliminated by this method without causing
appreciable harm to surrounding colon cells
[145], but in vivo studies have not been
conducted so far.
TOXIN-NEUTRALIZING AGENTS
Unlike the agents discussed above,
toxin-neutralizing drugs aim not to eliminate
C. difficile, but to prevent its cytotoxic effect on
colonocytes. These agents either sequester or
inactivate C. difficile toxins impeding them
from reaching their target cells, hence
preventing or alleviating the clinical
manifestations of CDI. Their use as
prophylactic or adjuvant therapy has a solid
scientific basis, but since they have no effect on
14 Infect Dis Ther (2017) 6:1–35
either vegetative C. difficile or its spores they do
not prevent asymptomatic carriage and
transmission.
Toxin Binding
Cholestyramine, an ion exchange resin usually
used as a bile acid sequestrant, was the first one of
the agents in this category to be tested more than
35 years ago [146]. There were various cases of
recurrent CDI reported to respond to
cholestyramine treatment by that time
[147, 148], but the compound was never tested
in any formal clinical trial. It does not seem to be
suitable as an adjunct therapy to vancomycin,
since it not only binds C. difficile toxins but the
antibiotic as well [70]. Based on the encouraging
results of a recent pilot study it was proposed to
be used as primary CDI prophylaxis in patients
receiving long-term systemic antibiotic
treatment [149], but these findings will have to
be confirmed in larger RCTs.
Tolevamer, a toxin-binding polymer, was a
compound of great expectations during the first
decade of this century [150, 151]. The initial
enthusiasm, however, flagged considerably in
light of more recent studies that proved its toxin
neutralization capacity to be much lower than
previously thought [152], and its clinical efficacy
failed to match that of vancomycin or
metronidazole in two clinical trials [153]. In
these trials, however, CDI recurrence rates were
significantly lower in the subset of patients that
responded to tolevamer than in the subsets of
responders in the vancomycin and the
metronidazole group [154]. These data may
adumbrate a potential use of tolevamer in CDI
prophylaxis in the future, although Genzyme
(now Sanofi Genzyme) indefinitely halted its
development after the unsuccessful trials.
Calcium aluminosilicate anti-diarrheal
(CASAD) is a naturally occurring clay known
to possess considerable cation exchange
absorbent properties. Its potential as a
prophylactic agent in cancer-related diarrhea
was recently investigated by Salient
Pharmaceuticals, with inconclusive results
[155, 156]. However, because of its in vitro
capacity to sequester C. difficile toxins [157], a
phase II trial was initiated to investigate its
efficacy as an adjuvant therapy of CDI, which
was prematurely terminated because of slow
enrollment [158].
Premature Toxin-Activation
Clostridium difficile takes advantage of a host
cytosolic enzyme, inositol hexakisphosphate,
that triggers an autocleavage process of the
toxins once these become endocytosed into
colonocytes, which results in their activation
and the subsequent cytotoxic effect. A novel
approach endeavors to combat CDI by the
premature luminal activation of C. difficile
toxins using an inositol hexakisphosphate
analog (INS-5010) where some of the
phosphate groups were substituted by sulfate
groups for stability purposes. C. difficile-infected
mice treated with this compound showed a
significant reduction of histological signs of
colitis as compared to control subjects [159].
The Swiss company developing INS-5010,
Inositec AG, has not yet announced the
initiation of human studies [160].
Passive Immunization
The potential of colostrum of pregnant cows
immunized with C. difficile toxoids
(hyperimmune bovine colostrum, HBC) to
inhibit the cytotoxic and enterotoxic effect of
C. difficile toxins has been known for more than
2 decades [161, 162]. Recently, it was proved to
alleviate symptoms of CDI in gnotobiotic
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piglets without detectably affecting normal
intestinal microbiota [163]. Whey protein
concentrate derived from immunized cow milk
was proved to be safe and well tolerated in
human subjects with CDI as well [164]. A
randomized phase II study comparing the
efficacy of immune whey with metronidazole
in the treatment of recurrent CDI showed
similar clinical results to the two treatment
modalities, but was terminated prematurely
because of the bankruptcy of the sponsor
(Novatreat Ltd.) [165].
The use of intravenous immunoglobuline
(IVIG) in CDI has been subject to discussion for
decades, but in the absence of evidence from
RCTs its potential benefits remain controversial
[166, 167]. There are only two relatively small
retrospective matched cohort studies published
that compare the clinical efficacy of the
addition of IVIG to conventional
anti-clostridial treatment [168, 169]. Neither of
them found significant differences between the
compared cohorts in the main clinical
outcomes, though the authors of one of these
studies point out that in their IVIG cohort there
were significantly older patients with more
severe CDI than in the control group [169].
The results of the first study on the efficacy
of monoclonal antibodies against C. difficile
toxin A (actoxumab, previously MK3415) and
toxin B (bezlotoxumab, previously MK6072 and
MDX1388) in a hamster model of CDI were
published exactly 10 years ago [170]. In that
study enhanced efficacy was observed with the
combination of the two antibodies in terms of
both recurrences and mortality. In a phase II
trial with this combination (a.k.a. MK-3415A),
the addition of the neutralizing antibodies to
standard CDI treatment also significantly
lowered recurrence rates [171]. However,
although the efficacy of bezlotoxumab in
preventing CDI recurrence was confirmed in
two recently conducted phase III trials, its
combination with actozumab, surprisingly, did
not show any additional benefit in these studies
[172]. Based on these results the US Food and
Drug Administration (FDA) has very recently
approved bezlotoxumab, and it will be available
in the first quarter of 2017 [173].
There are several other companies and
research entities as well focusing on
monoclonal antibodies against C. difficile
toxins. A mixture of anti-A and anti-B
neutralizing antibodies of ovine origin
(PolyCAB) is under research by MicroPharm,
which showed a significant reduction of CDI
recurrence in a hamster model [174]. Phase I
trials with this product are currently ongoing
[175]. UCB Pharma financed an investigation
with UCB MAb, a mixture of three humanized
antibodies (two against toxin A and one against
toxin B) that proved to be superior in terms of
survival after 28 days as compared to
bezlotoxumab in hamsters [176]. Another
mixture of humanized anti-A and anti-B
antibodies (CANmAbA4 and CANmAbB4) by
Emergent BioSolutions recently demonstrated
excellent in vitro toxin neutralizing capacity
and also conferred protection against clinical
CDI in a hamster model [177]. BliNK
Biomedical SAS, in turn, is developing a
cocktail consisting of an anti-A and two anti-B
monoclonal antibodies of entirely human
origin (MAb A2 ? MAb B1 ? MAb B2) with
very promising results in an animal study
published last year [178]. A novel bispecific
single-domain antibody, referred to as ABA,
with binding domains for both toxin A and B
demonstrated excellent toxin neutralization
activity in vivo and achieved a 100% survival
in mice with fulminant CDI caused by the
hypervirulent strain BI/NAP1/027 [179]. A
modified version of ABA, VNA2-Tcd, has
recently shown an outstanding protective
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capacity against CDI in another animal model
[180]. Apart from these, various other
monoclonal or single-domain antibodies
against the toxins or other structural
components (surface-layer proteins, flagella,
etc.) of C. difficile are subjects of investigation
currently, but none of these are in the clinical
(and most of them not even in in vivo
preclinical) phase of development yet [181].
ACTIVE IMMUNOTHERAPY
The preparation of the host immune system for
a potential encounter with C. difficile and its
toxins is the objective of this therapy. The most
advanced vaccines elicit a potent immune
response against toxins A and B, but—similarly
to toxin-neutralization—they do not lower
colonization rates, and their preventive value
manifests itself only on an individual level as
the transmission risk remains unaffected. Other
interesting vaccine candidates—which are in
much earlier stages of development—targeting
different surface components of C. difficile may
offer certain advantages in this sense in the
future.
Toxoid and Recombinant Toxin-Based
Vaccines
ACAM-CDIFF is a toxoid vaccine against both
toxin A and toxin B of C. difficile developed by
Sanofi Pasteur. After positive immunological
and clinical results obtained in a hamster model
[182] and in two phase I studies [183],
ACAM-CDIFF recently passed a phase II trial
without any safety issues [184]. A phase III RCT
with this vaccine is currently ongoing [185].
Pfizer is developing another toxoid vaccine
(PF-06425090) with good results obtained in a
phase I clinical trial [186], and two phase II
trials with this product are currently under way
in healthy adults [187].
VLA84 (a.k.a. IC84), a recombinant protein
vaccine containing epitopes of toxin A and
toxin B developed by Valneva, showed
positive results in a recent phase II trial in
terms of safety, tolerability and
immunogenicity in both younger adults and
elderly volunteers [188]. The vaccine is soon
to be tested in a phase III RCT, according to
the company [189].
DNA Vaccines
DNA vaccines have the theoretical advantage
over conventional vaccination of inducing
not only humoral but also cellular immune
response. The first DNA vaccine candidate for
C. difficile encoded the receptor-binding site
(RBD) of C. difficile toxin A [190]. Inoculated
mice produced a potent antibody response to
toxin A, and up to 100% survival was
observed (depending on vaccine formulation
and mouse strain) after challenge with a lethal
dose of toxin A [190].
In another mouse model, apart from the RBD
of toxin A, the N-terminal enzymatic domain of
toxin B also showed a positive antibody
response [191]. The combination of the
antibodies elicited by these two DNA vaccines
conferred 100% protection against C. difficile in
the experimental animals [191].
More recently, promising results were
published with a novel DNA vaccine that
contains plasmids encoding optimized RBDs of
both toxin A and B of C. difficile [192]. The sera
of immunized animals (mice and primates)
showed potent toxin neutralization ability
in vitro, and the combined vaccine provided a
50–90% protection against a lethal dose of C.
difficile spores in mice [192].
Infect Dis Ther (2017) 6:1–35 17
Vaccines Against C. difficile Surface
Antigens
Although toxin-based vaccine candidates may
successfully prevent toxin-mediated tissue
damage and lessen the clinical manifestations
of CDI, they do not prevent carrier status
because they have no effect on C. difficile
colonization. Vaccines targeting C. difficile
surface antigens (proteins or carbohydrates)
aim to offer a solution to this problem.
The surface layer protein (SLP) is the major
surface antigen of C. difficile. It is made up of an
outer layer formed by low-molecular-weight SLP
(LMW-SLP) and an inner layer formed by
high-molecular-weight SLP (HMW-SLP). These
two proteins are created from a common
precursor molecule (SlpA) that undergoes
enzymatic cleavage by a protease (Cwp84) once
SlpA reaches the cell surface. Intranasal or
intraperitoneal administration of crude SLP
(containing both HMW-SLP and LMW-SLP)
conferred only moderate protection against a
lethal C. difficile challenge in hamsters and mice
[193]. Intra-rectal vaccination with the precursor
protein SlpA in another animal study resulted in
slightly more favorable results, as it significantly
decreased the colonization level in the
vaccinated mouse group, though it also failed
to provide significant benefit in terms of survival
[194]. The immunogenicity and protective
ability of the protease Cwp84 have also been
investigated in hamsters: rectally administered
Cwp84 partially inhibited intestinal
colonization and significantly increased the
survival of hamsters challenged with C. difficile
in one study [195], and similar survival rates
(40%) were observed in another one with the
intragastric administration of the same vaccine
encapsulated in pectin beads [196].
Elements of C. difficile flagellum can also
be found among potential future vaccine
candidates. Recombinant flagellar cap
protein (FliD) in combination with either
Cwp84 or a mix of other flagellar proteins
administered rectally to mice resulted in
significantly lower colonization rates as
compared to control animals [197].
Intraperitoneal vaccination with
recombinant flagellin (FliC), on the other
hand, significantly improved survival in
mice and hamsters infected with C. difficile
in a recent study, while leaving the rest of the
intestinal microbiota apparently intact [198].
All three known surface polysaccharides of
C. difficile have been proved to be capable of
eliciting a certain level of immune response.
PS-I was first detected on the hypervirulent C.
difficile strain 027 but it is not specific to this
ribotype [199]. Conjugates of either synthetic
PS-I or its disaccharide minimal immunogenic
epitope with the diphtheria toxin variant
CRM197 proved immunogenic in mice [200].
Another murine model demonstrated the
immunogenicity of a conjugate vaccine of a
synthetic hexasaccharide epitope of PS-II with
CRM197 [201], and PS-II-specific immune
response was observed in swine as well after
being vaccinated with a non-adjuvanted PSI/
PSII preparation [199]. In a recent study a
conjugate vaccine of lipoteichoic acid (LTA,
a.k.a. PS-III) and CRM197 not only evoked
antigen-specific immune response in a mouse
model, but also significantly inhibited intestinal
C. difficile colonization [202].
There are a number of other potential C.
difficile vaccine candidates in the preclinical
phase of investigation that may be tested in
the clinical setting as well in the forthcoming
years [203, 204].
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RESTORATION AND MODULATION
OF THE INTESTINAL MICROBIOTA
Preservation and/or restoration of colonization
resistance of the intestinal microbiota is the
primary objective of the following therapies
with subsequent protection against toxigenic C.
difficile colonization or its elimination from the
colon. Among these methods there are some
that endeavor to offer the most complete
solution for the problem of CDI, aiming to
achieve clinical cure and the prevention of
carriage, transmission and recurrences all at
once.
Microbiota Restoration
The microbiota-restoring therapy par excellence
is intestinal microbiota transplantation, which
has been living a true renaissance in the last
years. Its excellent clinical efficacy is further
upheld by the observation that host intestinal
microbiota composition and diversity are
intimately linked to CDI severity and
recurrence risk [205].
That the restoration of an impaired intestinal
microbiota by transplanting feces of a healthy
individual may effectively cure CDI and prevent
recurrences is not questioned any more [1, 20].
Its efficacy was proven in two already published
phase II RCTs [206, 207], and another phase II
RCT performed on pediatric patients has also
recently been completed [208], whose results
are not yet available. Beside these completed
studies there are various ongoing phase II and
III RCTs with this treatment method [209].
With the demonstration that the efficacy of
previously recollected frozen and freshly
harvested microbiota have the same efficacy,
intestinal microbiota transplantation has
become a lot less cumbersome than before
[210, 211]. However, the manipulation of feces
and classical enteral administration methods
(i.e., by nasogastric tube, rectal enemas or via
colonoscopy) are not only laborious, but make
this procedure rather unattractive for physicians
and patients alike [212–214]. For this reason
there are a number of efforts being made to
enhance feasibility and social acceptance of this
highly efficient therapy. Oral administration of
capsulized intestinal microbiota is one of the
pioneer solutions for the above problem [215].
The elevated number of microbiota-containing
capsules to be administered, though, is a major
drawback of this method, which may be
improved by submitting microbiota to
lyophilization instead of simple freezing
[216, 217].
RBX2660 is a commercially available,
standardized microbiota suspension prepared
from human stool (Rebiotix Inc.) that
demonstrated its efficacy in a multicenter
open-label phase II study [218]. A phase IIb
RCT with this product has recently completed
enrollment, and if its results are favorable
RBX2660 is intended to enter phase III [219].
Seres Therapeutics has recently developed
SER-109, which contains around 50 species of
feces-derived Firmicutes spores after the
elimination of the rest of the microbiota with
ethanol. In an uncontrolled study, it was
administered orally in an encapsulated form to
30 patients with multiple CDI recurrences after
an appropriate response of standard of care
antibiotic treatment, and no further recurrences
were observed during the 8-week-long
follow-up in 96.7% of the subjects [220]. A
phase II trial to compare its efficacy with
placebo is currently recruiting participants
[221]. The same laboratory is investigating
another microbial preparation comprised of
spores of 12 different bacterial species
(SER-262) meant to prevent recurrence after
first CDI episodes [222]. An ongoing phase Ib
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RCT is currently evaluating the efficacy of this
product as compared to placebo [223].
MET-1 (Microbial Ecosystem Therapeutic-1)
is a defined intestinal bacterial culture
originating from a single donor. Two patients
with recurrent CDI who were treated with this
product experienced clinical cure in 2–3 days
and remained recurrence free for the 6
following months [224]. An open-label pilot
study is about to be initiated to demonstrate its
efficacy in recurrent CDI in comparison with
vancomycin [225].
The administration of nontoxigenic C.
difficile strains is another original approach to
prevent colonization by toxigenic C. difficile.
The most advanced research is being done with
the nontoxigenic C. difficile strain M3
(NTCD-M3, a.k.a. VP20621), with encouraging
results in animals [226] and in a recent phase II
placebo-controlled human trial as well [227].
Another nontoxigenic strain, CD37, also
provided significant protection against CDI in
a mouse model as observed by less weight loss
and less mortality in mice treated as compared
to untreated animals [228].
Bile Acid Therapy
The bile acid composition of the gut has an
important role in the upholding of colonization
resistance, as certain secondary bile acids
formed by members of a healthy microbiota
have an important role in the inhibition of C.
difficile spore germination [229]. The loss of this
effect due to the disruption of intestinal
microbiota by broad-spectrum antibiotic
treatment is a key factor in C. difficile
outgrowth, potentially leading to clinical CDI
[230]. A secondary bile acid, ursodeoxycholic
acid, was recently proved beneficial in a case of
refractory C. difficile-associated pouchitis [231],
but further evaluation of this compound in this
setting has not yet been undertaken. A
taurocholate analog, CamSA, is a potent
in vitro inhibitor of C. difficile germination
[232] that successfully prevented CDI in mice in
a dose-dependent manner [233]. Whether
secondary bile acids or their analogs will play
a role in CDI prevention or if they can also be
beneficial as adjunct in CDI treatment is still
unknown.
Intestinal Antibiotic Inactivators
CDI risk is intimately linked to the damage
systemic antibiotic therapy exerts on the
intestinal microbiota. Methods to avoid this
deleterious side effect by the inactivation of
antibiotics that reach the colon lumen promise
not less than the elimination of this single
major risk factor in cases when antibiotic
treatment is inevitable.
DAV132 is an activated-charcoal-based
product with enteric coating that successfully
adsorbs antibiotics such as amoxicillin or
moxifloxacin that reach the proximal colon
[234, 235]. This compound, developed by
DaVolterra, proved to prevent
moxifloxacin-induced CDI in an animal model
[236] and was demonstrated to be safe and
efficient in humans as well, in two phase I RCTs
[234, 235]. A dose-finding phase I RCT is
currently recruiting participants [237], and a
phase II trial in patients at risk of CDI is already
being prepared by the company [238].
The capacity of orally administered
beta-lactamase enzymes to inactivate
parenterally administered beta lactam
antibiotics secreted into the gut is the basis of
another approach to prevent antibiotic-induced
microbiota damage [239]. SYN-004 is a
recombinant beta-lactamase developed by
Synthetic Biologics that efficiently inactivated
intravenous ceftriaxone in the gut of dogs
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without interfering with serum antibiotic levels
[240]. Its efficacy and good tolerability were
recently proved by two phase I RCTs [241], and
three phase II trials are currently underway with
this product [241].
The same effect is sought by the research
group that colonized the gut of mice with
cephalosporinase-producing Bacteroides
thetaiotaomicron to evaluate its efficacy in
inactivating the intestinally excreted portion
of subcutaneously administered ceftriaxone
[242]. The investigators observed that the
cephalosporinase produced by B.
thetaiotaomicron successfully preserved normal
intestinal microbiota and prevented
colonization by both C. difficile and
vancomycin-resistant Enterococcus in treated
mice.
ENTEROPROTECTIVE AGENTS
These compounds are not explicitly
anti-clostridial agents, but seek to alleviate the
inflammation of the colon in CDI patients,
hence decreasing morbidity and improving
survival of severely ill patients.
Glutamine supplementation is traditionally
used to preserve and/or restore intestinal
mucosal integrity in patients with prolonged
parenteral nutrition, gastric ulcer,
chemotherapy, radiotherapy or intestinal
surgery, among other conditions.
Alanyl-glutamine is a bipeptide derived from
glutamine with enhanced stability and water
solubility. Its capacity both in vitro and in vivo
to counteract cytotoxic activity of C. difficile
toxins A and B was demonstrated in different
studies [243, 244]. In a mouse CDI model the
addition of alanyl-glutamine to vancomycin
treatment resulted in improved survival as
compared to vancomycin treatment alone
[244]. There is currently a phase II human trial
underway at the University of Virginia to test
the efficacy of alanyl-glutamine
supplementation in reducing mortality and
recurrences in CDI patients receiving standard
anticlostridial treatment [245].
The activation of adenosine A2A receptors in
macrophages and neutrophils has
anti-inflammatory and tissue-protective effects
by regulating the secretion of pro- and
anti-inflammatory cytokins. The combination
treatment with vancomycin and an adenosine
A2A receptor agonist (ATL370 or ATL1222)
resulted in less weight loss and better survival
in a mouse CDI model as compared with
vancomycin monotherapy [246]. Another
adenosine A2A receptor agonist, ATL313,
successfully prevented major damage of
murine ileal mucosa induced by C. difficile
toxin A [247]. The combination of
alanyl-glutamine and an ATL370 also
efficiently reversed histopathologic damage
caused by toxin A in another animal study
[248]. No human studies have been conducted
with these products for the time being.
CONCLUDING REMARKS
The number of potential therapies for CDI has
been growing steadily recently, and this trend
may continue for some years, as both the
incidence and severity of C. difficile keep
increasing, and current therapeutics cannot
offer a definite solution for this situation.
Antibiotic surveillance programs and more
directed anti-clostridial antibiotics have been
demonstrated to be useful, but the steadily
increasing number of susceptible hosts
(immunocompromised patients, elderly, etc.)
may prove these efforts insufficient to halt the
epidemic.
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It seems clear that none of the described
novel treatment methods will be able to deliver
the ultimate solution for CDI single-handedly,
since none of them can address all the
components of the compound objective of
CDI management, that is, primary
prophylaxis, cure and prevention of
recurrences. However, the more prophylactic
and therapeutic tools are available the more
efficient anti-CDI strategies can be tailored for
different patient populations in different
geographical areas with varying C. difficile
prevalence.
Certainly, the greatest impact on CDI
prevalence is to be expected from measures
that aim to prevent the infection by means of
active immunization or by protecting the
healthy intestinal microbiota. On the other
hand, the prompt restoration of a damaged
microbiota and potent and narrow spectrum
anti-clostridial antibiotics may guarantee a
quicker recovery in established CDI, hence
diminishing transmission and recurrence risk
alike. At the same time, anti-toxin and
anti-inflammatory treatment may improve the
clinical outcome in severe and/or complicated
CDI. As new therapeutic agents appear on the
market, efforts shall be made to find the optimal
way to combine them in a way that minimizes
incidence and horizontal transmission,
maximizes cure rates and keeps recurrences at
a minimum.
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